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ABSTRACT
Objective To compare the effectiveness of clomifene
citrate and unstimulated intrauterine insemination with
expectant management for the treatment of unexplained
infertility.
Design Three arm parallel group, pragmatic randomised
controlled trial.
Setting Four teaching hospitals and a district general
hospital in Scotland.
Participants Couples with infertility for over two years,
confirmed ovulation, patent fallopian tubes, and motile
sperm.
Intervention Expectant management, oral clomifene
citrate, and unstimulated intrauterine insemination.
Main outcome measures The primary outcome was live
birth. Secondary outcome measures included clinical
pregnancy, multiple pregnancy, miscarriage, and
acceptability.
Results 580 women were randomised to expectant
management (n=193), oral clomifene citrate (n=194), or
unstimulated intrauterine insemination (n=193) for six
months.Thethreerandomisedgroupswerecomparablein
termsofage,bodymassindex,durationofinfertility,sperm
concentration, and motility. Live birth rates were 32/193
(17%), 26/192 (14%), and 43/191 (23%), respectively.
Comparedwithexpectantmanagement,theoddsratiofora
live birth was 0.79 (95% confidence interval 0.45 to 1.38)
after clomifene citrate and 1.46 (0.88 to 2.43) after
unstimulated intrauterine insemination. More women
randomised to clomifene citrate (159/170, 94%) and
unstimulated intrauterine insemination (155/162, 96%)
found the process of treatment acceptable than those
randomised to expectant management (123/153, 80%)
(P=0.001 and P<0.001, respectively).
ConclusionIncoupleswithunexplainedinfertilityexisting
treatmentssuchasempiricalclomifeneandunstimulated
intrauterineinseminationareunlikelytooffersuperiorlive
birth rates compared with expectant management.
Trial registration ISRCT No: 71762042
INTRODUCTION
Infertilityaffectsoneinsevencouples
1andisdescribed
as unexplained when standard investigations (semen
analysis, tubal patency tests, and assessment of ovula-
tion) fail to find any abnormalities. Unexplained
infertility affects a quarter of infertile couples,
1 some
ofwhomhaveareasonablechanceofspontaneouslive
birth.
2 Expectant management, however, is not a
popular option, and several empirical interventions
have been used for many years without rigorous prior
evaluation. Commonly used first line treatments for
unexplained infertility include clomifene citrate and
intrauterine insemination.
3-5
Oral clomifene citrate, a popular choice for the
treatment of unexplained infertility, is inexpensive,
requires little clinical monitoring, and is thought to
correct subtle ovulatorydysfunction.
3 Concernsabout
multiple pregnancies induced by clomifene and a
potentialriskofovariancancer,however,underlinethe
need to weigh the risks and benefits.
5-7
Intrauterine insemination of sperm can potentially
enhance pregnancy rates by helping to overcome the
cervicalbarrier.Observationaldatasuggestathreefold
increaseinpregnancyrateswithintrauterineinsemina-
tion alone, with a further increase with concomitant
ovarian stimulation with gonadotrophin
(superovulation).
8
Superovulation with intrauterine insemination is
superior to unstimulated intrauterine insemination,
9
but gonadotrophins can cause ovarian hyperstimula-
tionandmultiplepregnancy.
1011Arecenttrialfailedto
show any advantage of superovulation with intra-
uterine insemination over expectant management in
selected couples with a good chance of spontaneous
pregnancy
12 and Goverde et al failed to show any
superiority over unstimulated intrauterine
insemination,
13 but there are no adequately designed
trials of unstimulated intrauterine insemination versus
expectantmanagement.Thecurrentrecommendation
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Systematicreviewshaveexposedtheunevenquality
in methods of primary studies and the uncertainties of
the available evidence.
347814 They have highlighted
the need for a definitive trial with adequate power to
assess the effectiveness of clomifene citrate and
unstimulatedintrauterineinseminationinunexplained
subfertility.
We compared the clinical effectiveness and cost of
these commonly used treatments against expectant
management. We focus here on clinical outcomes.
METHODS
Study design
The study was a three arm, parallel group, pragmatic
randomised controlled trial. We recruited patients
from four major teaching hospitals and one district
general hospital in Scotland. Inclusion criteria were at
least two years of infertility, bilateral tubal patency
(demonstrated by laparoscopy or hysterosalpingogra-
phy), ovulation demonstrated by appropriately timed
mid-luteal progesterone, and normal semen variables
(accordingtoWorldHealthOrganizationcriteria).We
also included coupleswith minimum sperm motility of
20% or minimal endometriosis (rAFS stage 1).
Expectant management—This involved six months
during which no clinic visits or medical interventions
were scheduled. Couples were given general advice
regarding the need for regular intercourse, but no
specific measures such as basal temperature charts or
luteinising hormone kits were recommended.
Clomifene citrate—Women randomised to clomifene
citratereceivedanoraldoseof50mgbetweendaytwo
and six of each treatment cycle. During the first cycle
they underwent a transvaginal scan and mid-luteal
progesterone check. Subsequent cycles were mon-
itored by a mid-luteal progesterone check alone.
Couples were advised to have intercourse on days 12-
18 of the cycle. If three or more ovarian follicles were
detected by scan in the first cycle, the cycle was
cancelled and the couple advised to avoid intercourse.
In the next cycle, women who were overstimulated on
the first cyclestarted on a reduced dose of clomifene
(25 mg) and were monitored in the same way as they
would be for a first cycle (that is, scan on day 12 and
blood test for progesterone on day 21) with a further
reductiontoalternatedaysof25mgofferedinthenext
cycle if necessary. As women were known to be
ovulatory, we did not anticipate progesterone concen-
trations to indicate non-ovulation. A single low mid-
luteal progesterone concentration (suggestive of ano-
vulation) could be attributed to a mistimed blood test
and, given the pragmatic nature of the trial, did not
result in a change of protocol. In the event of low
concentrations in successive cycles, we intended to
treat the women as anovulatory using the standard
clinic protocol of incremental doses of clomifene.
Intrauterine insemination—Women were asked to
monitor mid-morning urinary luteinising hormone
concentrations from day 12 of their cycle using
Clearview (Unipath, Bedford). A single insemination
was performed 20-30 hours after an endogenous surge
was detected. Semen was prepared with a swim-up
technique with Puresperm (Nidacon, Hunter Scienti-
fic, Saffron Walden, Essex) density gradient followed
by resuspension in a sperm buffer. A maximum of
0.5 ml suspension of processed spermatozoa was
introduced into the uterine cavity through the cervix
with a 10 cm intrauterine insemination catheter.
Couples were advised to avoid intercourse from day
12ofthecycle untilthe dayofinsemination.Awoman
who missed a luteinising hormone surge did not
receive intrauterine insemination in that cycle but
continued to monitor luteinising hormone concentra-
tions in the next cycle, with a view to insemination as
originally planned.
Randomisation and follow-up
An independent statistician generated the randomisa-
tion allocation sequence. Research nurses enrolled
participants at each centre and assigned them to their
groupsusingacentraltelephonerandomisationsystem
based in Aberdeen (the coordinating centre). The
minimisation algorithm balanced allocation of treat-
ment by maternal age, parity, and duration of
subfertility. Women were stratified by centre, and
blinding was not possible because of the nature of the
interventions. The duration of intervention was six
months. All five recruiting centres followed standar-
dised written treatment protocols relating to drug
doses, counselling before treatment, ultrasound scans,
and laboratory tests. Information sheets for patients
relatingtotreatmentortimingofintercoursewerealso
similar.
Allocated to expectant
management (n=193)
Allocated to clomifene
citrate (n=194)
Allocated to intrauterine
insemination (n=193)
Included in analysis of
live birth (n=193, 100%)
Included in analysis of
live birth (n=192, 99%)
Included in analysis of
live birth (n=191, 99%)
Lost to follow-up
(n=0)
Received only allocated
  treatment (n=187, 97%)
Received alternative
  treatment (n=6, 3%)
    Clomifene citrate (n=3)
    Intrauterine 
      insemination (n=3)
Received only allocated
  treatment (n=168, 87%)
Received alternative
  treatment (n=26, 13%)
    Expectant management (n=24)
    Intrauterine 
      insemination (n=2)
Received only allocated
  treatment (n=160, 83%)
Received alternative
  treatment (n=33, 17%)
    Expectant management (n=32)
    Clomifene citrate (n=1)
Excluded (n=404, 41%):
  Did not meet eligibility criteria (n=184)
  Refused to give consent (n=220)
Lost to follow-up
(n=2, 1%)
Lost to follow-up
(n=2, 1%)
Assessed for eligibility (n=984)
Randomised (n=580, 59%)
Fig 1 | Trial flow chart
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randomisation. A pregnancy test was performed two
weeksafterintrauterineinseminationor(intheabsence
of a period) by day 28 in the other groups. Clinical
pregnancy was confirmed by the presence of an
intrauterine gestational sac on ultrasonography, with
a fetalheartbeat fiveweekslater.Womenwhobecame
pregnant but later miscarried within six months of
randomisation were allowed to have further treatment
intheirrandomisedgroupsfortherestoftheirallocated
time. We included spontaneous pregnancies in the
clomifenecitrateandintrauterineinseminationarmsin
the final analysis.
Outcomes
The primary outcome was live birth per woman.
Secondary outcomes included clinical pregnancy rate
per woman, multiple pregnancy rate, acceptability,
adverse events, anxiety, and depression.
Research nurses completed structured records of
clinicalandproceduraldetails.Weusedquestionnaires
completed by women at randomisation and at six
months to collect data on acceptability of treatment,
side effects, anxiety, and depression. Anxiety and
depression were measured with the hospital anxiety
and depression scale, with scores of 11 or more
suggestive of the relevant mood disorder.
15 Women
were asked to describe how acceptable their treatment
was with respect to the process and outcome of their
treatment separately by using Likert items with six
possible responses, ranging from “totally acceptable”
to “totally unacceptable.” Women who were pregnant
at six months after randomisation were followed up to
obtain data on delivery.
Statistical analysis
Wedesignedthistrialtotesttwoprimarycomparisons:
expectant management versus clomifene citrate and
expectant management versus unstimulated intra-
uterineinsemination.Weaimedtorecruit190 couples
ineachgroup(1:1:1)—atotalof570couples(including
an allowance for a 10% loss to follow-up).
Weestimatedthatsixmonthsofexpectanttreatment
wouldbeassociatedwithalivebirthrateof10%.
2Based
on the pooled odds ratio of 2.4 in favour of clomifene
reported in the Cochrane review by Hughes et al
14 at
the time the study was designed in 2001, we envisaged
that we needed 168 women in each group to show a
clinically meaningful improvement in live birth out-
comes(from10%to22%; oddsratio2.5)forclomifene
versus expectant management, with 80% power at the
5% level of significance. Our proposed sample size
would allow detection of a similar difference between
expectant management and unstimulated intrauterine
insemination (10% to 22%; odds ratio 2.5). In a
randomised trial of unstimulated versus stimulated
intrauterineinseminationversusinvitrofertilisationby
Goverdeetal,
13thecumulativelivebirthrateincouples
undergoing unstimulated intrauterine insemination
was 31%. Taking these data into account, along with
the invasiveness of the treatment and the perceived
benefittocouples,weexpectedtohaveinexcessof95%
power to detect a difference in live birth rates of 20%
(10%to30%;oddsratio4)betweenexpectantmanage-
ment and unstimulated intrauterine insemination .
If both active treatments (clomifene citrate and
unstimulated intrauterine insemination) were found
to be more effective than expectant management, we
anticipated having over 85% power at the 5% level of
significance to detect an absolute difference of 15%
(15% to 30%) in live birth rates between the active
treatment groups.
Data were entered on a computer held database and
analysed with SPSS for Windows (SPSS, Chicago, IL;
version 14). The analysis strategy was defined a priori
andaddressedtheclinicallyrelevantcomparisons.Our
primary aim was to compare clomifene citrate versus
expectant management and unstimulated intrauterine
insemination versus expectant management. We
intended to compare the two active treatments only if
both were found to be superior to expectant manage-
ment.Wedecidednottoconductaglobaltestacrossall
three groups as the direct comparisons were of clinical
relevance.
16 We used intention to treat analyses
throughout, with a secondary per protocol analysis
conducted on live birth rates only. We analysed
categorical variables with χ
2 tests, used logistic regres-
sionmodelstoadjustformaternalage,parity,duration
of infertility, and recruitment centre, and calculated
odds ratios with confidence intervals (95% for the
primary outcome, 99% for secondary outcomes). On
the basis of the crude live birth rates and 95%
confidence intervals for the absolute risk reductions
calculatedwithNewcombe’smethodfortwounpaired
proportions,
17 we computed the numbers needed to
treatforbenefit(NNB)orharm(NNH)asappropriate,
Table 1 |Baseline characteristics at randomisation according to allocation to expectant
management, clomifene citrate, or unstimulated intrauterine insemination for unexplained
infertility. Figures are numbers (percentages) unless stated otherwise
Expectant
management (n=193)
Clomifene citrate
(n=194) Insemination (n=193)
Mean (SD) age (years):
Women 32 (3.4) 32 (3.5) 32 (3.7)
Men 34 (5.1) 34 (5.1) 34 (5.2)
Median (IQR) duration of
infertility (months)
30 (25-38) 30 (24-38) 30 (25-40)
Primary infertility 135 (70) 144 (74) 134 (69)
Mild endometriosis, 17 (9) 9 (5) 13 (7)
Surgical treatment for
endometriosis*
3 (18) 2 (22) 1 (8)
Mild male factor infertility 9 (5) 11 (6) 14 (7)
Median (IQR) BMI (women) 23 (21-25) 23 (22-26) 23 (21-26)
Sperm variables:
Median (IQR) density
(million/ml)
62 (39-95) 65 (38-105) 58 (35-98)
Mean (SD) motility % 52 (15.6) 53 (16.4) 53 (15.6)
HADS subscale ≥11:
Anxiety 29 (15) 28 (14) 23 (12)
Depression 3 (2) 1 (1) 2 (1)
IQR=interquartile range; BMI=body mass index; HADS=hospital anxiety and depression scale.
*Percentage of those who had mild endometriosis.
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comparedtimetopregnancyleadingtoalivebirthwith
log rank tests, then used Cox proportional hazards
models to make adjustments. Interaction tests for
subgroup analyses (planned a priori) were obtained
with logistic regression modelling live birth per
woman. Responses to the questions regarding the
acceptability of treatment were grouped into “accep-
table”or“unacceptable”forthepurposesofanalysis.A
P value of 0.05 was considered significant for the
primaryoutcome,whileavalueof0.01wasusedforall
secondary outcomes.
RESULTS
A total of 580 couples were recruited between
September 2001 and September 2005 (fig 1).
Baseline characteristics
The three groups (expectant management, clomifene
citrate, and intrauterine insemination) were compar-
able in terms of women’s age, men’s age, BMI, semen
variables, and proportion of couples with primary
infertility (table 1). The median duration of infertility
was 30 months in each of the randomised groups and
only a few individuals (under 10%) had endometriosis
or mild male factor infertility problems.
Active treatments
Ofthe194womenrandomisedtoclomifenecitrate,93
(48%) received six completed cycles of clomifene
citrate and 18 (9%) received none over the six month
trial period. During the trial period, 37/193 (19%)
w o m e nr a n d o m i s e dt ou n s t i m u l a t e di n t r a u t e r i n e
insemination received six completed cycles of intra-
uterine inseminationand 26 (13%) received none. The
median (interquartile range) number of treatment
cycles received was 5 (2-6) for the clomifene citrate
group and 4 (2-5) for the intrauterine insemination
group.
Of the 883 cycles where the intention was for the
women to receive clomifene, 31 (4%) cycles in 20
women resulted in an exaggerated response (three or
more follicles). There were 785 cycles where the
intention was for the women to receive intrauterine
insemination; 25 (3%) of these cycles resulted in
missing the luteinising hormone surge and 13 women
missed the surge at least once.
Live birth
Live birth rates in the three randomised groups were
32/193 (17%) for expectant management, 26/192
(14%) for clomifene citrate, and 43/191 (23%) for
unstimulated intrauterine insemination (table 2).
Three women (2%) in the clomifene citrate group and
14(7%)intheintrauterineinseminationgroupbecame
pregnant spontaneously and had a live birth. Com-
pared with expectant management, the odds ratio of a
live birth was 0.79 (95% confidence interval 0.45 to
1.38)withclomifenecitrateand1.46(0.88to2.43)with
unstimulated intrauterine insemination. Adjustment
for maternal age, parity, duration of infertility, and
recruitmentcentre gave similar results(table 2), asdid
the per protocol analysis.
Thenumberneededtotreatforharmwithclomifene
citratewas33(95%confidenceintervalNNH10to∞to
NNB 24). This indicates that if 33 women were treated
with clomifene citrate, one fewer would have a live
birth than if they all received expectant management,
with the confidence interval indicating the uncertainty
oftheestimate.Thenumberneededtotreatforbenefit
with unstimulated intrauterine insemination was 17
(NNH51to∞toNNB7).Therefore,17womenwould
need to undergo intrauterine insemination rather than
expectant management for one additional woman to
have a livebirth, withthe rangeoflikely valuesforthis
estimate given by the confidence interval.
There were no significant differences in the time to
pregnancyleadingtoalivebirthwithclomifenecitrate
(P=0.41) or unstimulated intrauterine insemination
(P=0.17)comparedwithexpectantmanagement(fig2).
Compared with expectant management, the adjusted
hazardratioforthetimetoapregnancyleadingtoalive
birth was 0.83 (99% confidence interval 0.42 to 1.63)
Table 2 |Analysis of live birth for expectant management compared with clomifene citrate or unstimulated intrauterine insemination
Analysis
No (%) in expectant
management group
Clomifene citrate v expectant management Intrauterine insemination v expectant management
No (%)
OR (95% CI), P value
No (%)
OR (95% CI), P value
Crude Adjusted* Crude Adjusted*
Intention to treat 32/193 (17) 26/192(14) 0.79 (0.45 to 1.38), 0.49 0.80 (0.45 to 1.42), 0.45 43/191 (23) 1.46 (0.88 to 2.43), 0.18 1.53(0.91to2.56),0.11
Per protocol 30/187 (16) 24/175(14) 0.83 (0.47 to 1.45), 0.64 0.83 (0.46 to 1.50), 0.53 31/167 (19) 1.19 (0.69 to 2.07), 0.63 1.25(0.71to2.18),0.44
*Adjusted for maternal age, parity, duration of infertility, and recruitment centre.
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Fig2 |Timetopregnancyleadingtolivebirthingroupsallocated
to clomifene citrate, expectant management, or unstimulated
intrauterine insemination. For women with live birth, time to
event was defined as number of months between
randomisation and estimated date of last menstrual period;
womenwithoutlivebirthwerecensoredatendoftheirfollow-up
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unstimulated intrauterine insemination.
The subgroup analyses for live birth per woman
foundnomodifiersoftheeffectsofclomifenecitrateor
unstimulatedintrauterineinseminationcomparedwith
expectantmanagement(table 3).Thetreatmenteffects
were similar between couples with and without pure
unexplained infertility, between couples with and
without mild male factor infertility, and between
couples with primary and secondary infertility. The
number of live births in each subgroup and treatment
combination, however, was small.
Secondary outcomes
Table 4 shows other clinical outcomes in the three
randomised groups. Clinical pregnancy rates were
comparable between expectant management and
clomifene citrate (17% v 15%) and expectant manage-
mentandunstimulatedintrauterineinsemination(17%
v 23%). Rates of miscarriage and ectopic pregnancy
were also similar in the two comparisons,as were rates
of multiple pregnancy.
Side effects including abdominal pain, bloating, hot
flushes, nausea, and headaches were more common in
the clomifene citrate group than in the other groups,
affectingabout10-20%ofwomen.Despitethis,women
on active treatments found the process of treatment
more acceptable than those randomised to expectant
management. The proportion of women scoring 11 or
more on the anxiety or depression subscales at six
months was similar across the three groups.
DISCUSSION
Clomifene citrate or unstimulated intrauterine insemi-
nation seems to be no more effective than expectant
management in couples with unexplained infertility.
Strengths and weaknesses
We compared the effectiveness of both clomifene
citrate and unstimulated intrauterine insemination
versus expectant management. The inclusion of a
controlgroup(expectantmanagement)meansthatour
results reflect the true marginal effect of these popular
interventions. The trial is strengthened by its prag-
matic,multicentreapproachandthechoiceoflivebirth
per woman as its end point. We exceeded our
recruitment target with less than 1% loss to follow-up;
in addition, the number of women in the expectant
management and clomifene citrate arms exceeded the
number randomised in all of the previous clomifene
citrate trials pooled together.
14
The inclusion of cases of mild male factor infertility
and minimal endometriosis might have introduced an
element of clinical heterogeneity. The presence of
these cases in this pragmatic trial, however, can be
justified on the grounds that they are managed in the
same way as “true” unexplained infertility.
6 Although
there were few live births within each subgroup,
subgroup analyses indicate similar treatment effects
inthesegroups.Ourchoiceofclinicalprotocolsforthe
intervention arms reflects current practice in Scotland
and the rest of the UK,
7 but the results might not be
generalisabletootherpopulationsandalternativedrug
regimens. In particular, this trial does not address the
issue of a combined approach with clomifene citrate
and intrauterine insemination, which should be the
focus of future trials.
Interpretation within context of setting and intervention
At the time this trial was conducted, the Cochrane
review on clomifene citrate in unexplained infertility
suggested that it had a beneficial effect and supported
its use on grounds of low cost and ease of
Table 3 |Subgroup analysis of live birth by diagnostic group for expectant management compared with clomifene citrate or
unstimulated intrauterine insemination, with crude and adjusted P values*
No (%) in expectant
management group
Clomifene citrate v expectant
management
Intrauterine insemination v expectant
management
No (%) Crude Adjusted† No (%) Crude Adjusted†
All 32/193 (17) 26/192 (14) —— 43/191 (23) ——
Pure unexplained infertility:
No 6/26 (23) 3/19 (16)
0.73 0.76
5/26 (19)
0.33 0.28
Yes 26/167 (16) 23/173 (13) 38/165 (23)
Mild male infertility factor:
No 30/184 (16) 23/181 (13)
0.61 0.53
41/177 (23)
0.39 0.25
Yes 2/9 (22) 3/11 (27) 2/14 (14)
Mild endometriosis:
No 28/176 (16) 26/183 (14)
——
40/178 (22)
0.62 0.68
Yes 4/17 (24) 0/9 3/13 (23)
Mild male infertility factor and mild endometriosis:
No 32/193 (17) 26/191 (14)
——
43/190 (23)
——
Yes 0/0 0/1 0/1
Type of infertility:
Primary 24/135 (18) 19/142 (13)
0.59 0.47
29/132 (22)
0.49 0.39
Secondary 8/58 (14) 7/50 (14) 14/59 (24)
*For treatment*subgroup interaction term.
†Adjusted for maternal age, parity, duration of infertility, and recruitment centre.
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14FertilityguidelinesintheUKandthe
United States endorsed this view
57but highlighted the
needforadefinitivetrial.Whileboth100mgand50mg
of clomifene citrate have been used in previous trials,
our decision to use the lower dose in this cohort of
ovulatory women was guided by concerns about the
risk of high order multiple pregnancy.
18 The rationale
for ovarian stimulation in women with documented
ovulation has been to correct subtle disorders of
ovulation not identified by conventional tests and to
increase the number of oocytes per cycle.
3 Yet, as an
agonist-antagonist at the level of the oestrogen
receptor, antioestrogenic effects of clomifene citrate
ontheendometrium,uterinebloodflow,andqualityof
cervical mucus could affect its ability to enhance
pregnancy rates.
19 A recent placebo controlled trial
with 140 women with unexplained infertility failed to
show higher rates of live birth after treatment with
100 mg clomifene citrate.
20
Concern about iatrogenic multiple pregnancies has
influenced a national guideline in the UK to advocate
the use of unstimulated intrauterine insemination.
7 A
Cochrane review showed the rate of live birth to be
higher with stimulated intrauterine insemination but
found no suitable trials comparing unstimulated intra-
uterine insemination with expectant management.
21
The only relevant trial in the literature used intra-
uterineinseminationcyclesastheunitofanalysisanda
crossover design but did not provide outcome data
from before the crossover.
22 A recent trial showed that
superovulation with intrauterine insemination offered
no advantage in a subgroup of couples with unex-
plained infertility with a good chance of spontaneous
pregnancy.
12 Recruited couples, however, had a
shorter duration of infertility than in our trial and
henceahigherexpectationofspontaneouspregnancy.
2
Incontrast,ourtrialessentiallycomparesbothfirstline
treatments (clomifene citrate and unstimulated
Table 4 |Analysis of secondary outcomes for expectant management compared with clomifene citrate or unstimulated intrauterine insemination
No (%) in expectant
management group
Clomifene citrate v expectant management Intrauterine insemination v expectant management
No (%)
OR (99% CI), P value
No (%)
OR (99% CI), P value
Crude Adjusted* Crude Adjusted*
Clinical pregnancy per
woman†
33/193 (17) 29/192 (15) 0.86 (0.42 to 1.76),
0.69
0.88 (0.42 to 1.82),
0.64
43/191 (23) 1.41 (0.73 to 2.74),
0.23
1.47 (0.75 to 2.89),
0.14
Multiple clinical
pregnancy per woman‡
2/193 (1) 2/192 (1) 1.01 (0.08 to 13.39),
1.00
— 1/191 (1) 0.50 (0.02 to 11.92),
1.00
—
Miscarriage¶ 14/46 (30) 10/38 (26) 0.82 (0.23 to 2.87),
0.86
— 9/55 (16) 0.45 (0.13 to 1.56),
0.15
0.35 (0.09 to 1.40),
0.05
Ectopic pregnancy¶ 1/46 (2) 0/38 (0) P=1.00 — 2/55 (4) 1.70 (0.07 to 41.56),
1.00
—
Preterm birth§ 5/31 (16) 3/26 (12) 0.68 (0.09 to 5.12),
0.72
— 6/43 (14) 0.84 (0.16 to 4.59),
1.00
—
Treatment related
hospital admission
2/160 (1) 2/168 (1) 0.95 (0.07 to 12.71),
1.00
— 0/163 (0) P=0.25 —
Abdominal pain 5/159 (3) 40/169 (24) 9.55 (2.71 to 33.67),
<0.001
9.76 (2.75 to 34.65),
<0.001
12/164 (7) 2.43 (0.60 to 9.88),
0.15
—
Vaginal bleeding 4/159 (3) 7/165 (4) 1.72 (0.33 to 8.86),
0.58
1.65 (0.32 to 8.66),
0.44
10/164 (6) 2.52 (0.53 to 11.88),
0.19
—
Nausea 4/159 (3) 22/166 (13) 5.92 (1.42 to 24.78),
0.001
6.14 (1.43 to 26.44),
0.001
3/164 (2) 0.72 (0.10 to 5.28),
0.72
—
Vomiting 0/158 (0) 1/165 (1) P=1.00 — 0/164 (0) ——
Headache 6/159 (4) 33/167 (20) 6.28 (1.92 to 20.50),
<0.001
6.43 (1.95 to 21.25),
<0.001
4/164 (2) 0.64 (0.12 to 3.45),
0.54
—
Hot flushes 4/159 (3) 30/170 (18) 8.30 (2.04 to 33.79),
<0.001
8.63 (2.10 to 35.49),
<0.001
0/164 (0) ——
Bloating 0/158 (0) 33/168 (20) P<0.001 — 6/164 (4) ——
Process of treatment
acceptable
123/153 (80) 159/170 (94) 3.53 (1.35 to 9.20),
0.001
3.77 (1.42 to 9.99),
<0.001
155/162 (96) 5.40 (1.75 to 16.64),
<0.001
5.55 (1.78 to 17.25),
<0.001
Outcome of treatment
acceptable
82/148 (55) 100/168 (60) 1.18 (0.66 to 2.13),
0.53
1.20 (0.66 to 2.17),
0.44
117/159 (74) 2.24 (1.20 to 4.21),
0.001
2.27 (1.19 to 4.31),
0.001
HADS subscale ≥11:
Anxiety 31/171 (18) 34/175 (19) 1.09 (0.54 to 2.21),
0.86
1.09 (0.53 to 2.25),
0.75
22/173 (13) 0.66 (0.30 to 1.43),
0.22
0.64 (0.29 to 1.42),
0.15
Depression 4/170 (2) 4/174 (2) 0.98 (0.16 to 6.17),
1.00
— 2/172 (1) 0.49 (0.05 to 4.63),
0.45
—
HADS=hospital anxiety and depression scale.
*Adjusted for maternal age, parity, duration of infertility, and recruitment centre.
†At least one fetal heart beat seen on ultrasound.
‡At least two fetal heart beats seen on ultrasound.
¶Denominator is biochemical pregnancy (positive pregnancy test).
§Gestation period ≤37 weeks; denominator is live births with known gestation period.
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an unselected population with mixed prognosis and
includes clinical and cost effectiveness as outcomes. It
was previously believed that technical and procedural
aspects of intrauterine insemination could influence
the outcome of treatment. A systematic review has
failed to confirm the superiority of double insemina-
tion over single insemination (as performed in this
trial).
23 Fewer than 20% of couples randomised to
unstimulated intrauterine insemination received six
cycles of treatment over the six month trial period. It
has been noted in a previous trial that not all couples
randomised to intrauterine insemination treatment
receive their full quota of six cycles within this time
period.
13 We cannot exclude the possibility that
exposure to more cycles of intrauterine insemination
could have led to a higher live birth rate, but for
practical reasons we needed to stipulate a time
dependent exposure to the trial intervention.
Ourresultsalsoshowthatwomenwithinfertilityare
reassuredbyactivetreatmentandarelesssatisfiedwith
an expectant approach. Similar concerns in the past
havelimitedthenumberoffertilitytrialswithacontrol
arm.
2Comparableanxietyanddepressionscoresinthe
randomised groups suggest that preference for active
treatment did not translate into greater mental well-
being in those randomised to clomifene citrate or
unstimulatedintrauterineinsemination.Asbothactive
treatmentshaveresourceimplications,informationon
the costsof the twotreatmentsis importanttoconsider
and will be reported elsewhere.
Interpretation of our findings needs to take into
account the population sampled. We are unable to
provide demographic information on those women
whodidnotagreetoparticipateinthistrialaswehadno
ethical approval to collect such data. Criteria for the
diagnosis of “true” unexplained infertility are still
debatable.
24 Accurate diagnosis is influenced by the
nature, number, and precision of the tests used. The
presenttrendtowardsalessinvasiveapproachtotubal
patency testing
712 is supported by data showing that
additional laparoscopy after hysterosalpingography
does not enhance the success of unstimulated intra-
uterine insemination.
25 Without routine laparoscopy,
however, it is impossible to exclude the possibility of
endometriosis.
Statistical approach
An approach commonly adopted in multi-arm trials
involves undertaking one global test across all treat-
ment groups. Such tests do not identify which
treatments are different and can have limited power
todetectgenuinedifferences.
26Wedesignedourtrialto
make direct comparisons with a control (expectant
management); therefore, there was a logical basis for
performing separate significant tests for each active
treatmentversusexpectantmanagement.
1626Knowing
which of the active treatments is the more effective is
clinically relevant only if both treatments prove to be
superior to expectant management.
As recommended and planned a priori, we adjusted
our results for the minimisation and stratification
factors used in the randomisation scheme
27 but have
also presented crude results so that the impact of these
adjustments can be assessed. As some women did not
receivetheirrandomisedtreatment,wepresentedaper
protocol analysis of live birth rates, along with the
intention to treat analysis, to investigate what effects
this might have on our conclusions. We found that
unstimulated intrauterine insemination did not
enhance live birth, though the upper limit of the 95%
confidence interval for the number needed to treat to
benefit was 7, a figure that might be perceived to be
clinically worthwhile.
Conclusions
Spontaneous live birth rates in a randomised cohort of
women with unexplained infertility do not seem to be
enhancedbycommonfirstlinetreatments—clomifene
citrate or unstimulated intrauterine insemination.
These results challenge current practice, as endorsed
by a national guideline in the UK.
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